We are live on ! Find out more

218 hedge funds and large institutions have $1.62B invested in Genmab in 2023 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 75 increasing their positions, 94 reducing their positions, and 42 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more call options, than puts

Call options by funds: $6.37M | Put options by funds: $4.18M

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.25% less ownership

Funds ownership: 6.94% → 6.68% (-0.25%)

8% less funds holding

Funds holding: 238 → 218 (-20)

20% less repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 94

38% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 42

41% less capital inflows, than outflows

Capital inflows: $128M | Capital outflows: $216M

Holders
218
Holders Change
-20
Holders Change %
-8.4%
% of All Funds
3.47%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
26
Increased
75
Reduced
94
Closed
42
Calls
$6.37​M
Puts
$4.18​M
Net Calls
+$2.19​M
Net Calls Change
+$2.55​M

GMAB Hedge Fund Activity: Q1 2023 in Review

218 of the 6,291 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q1 2023, worth a combined $1.62B — down 16% from $1.94B a quarter earlier.

Sellers outnumbered buyers: 42 funds closed out of GMAB and 26 opened new positions — a net loss of 16 holders — while 94 trimmed existing stakes and 75 added.

The largest buyer was Envestnet Asset Management, adding an estimated $22.5M. The largest seller was Arrowstreet Capital, cutting an estimated $28.5M.

  • 218 institutional investors held Genmab (GMAB) as of Q1 2023, down from 238 in Q4 2022.
  • Funds reported $1.62B of Genmab stock for Q1 2023, down 16% quarter-over-quarter.
  • 26 funds opened new Genmab positions in Q1 2023 and 42 closed out, a net change of -16 holders.
  • The largest Genmab buyer in Q1 2023 was Envestnet Asset Management, an estimated $22.5M added.
  • The largest Genmab seller in Q1 2023 was Arrowstreet Capital, an estimated $28.5M sold.

Based on aggregated 13F filings for Q1 2023.